Logo

Cowen & Co.

TD Cowen, JP Morgan Initiate Coverage of Tempus AI With Buy, Overweight Ratings

Cowen said that Tempus is a differentiated oncology diagnostics company with an order backlog from pharma clients and the potential for strong growth and rising margins.

TD Cowen Initiates Coverage of MDxHealth With Outperform Rating

Analyst Dan Brennan wrote in a note to investors that the company's position in an under-penetrated market bodes well for future revenue growth.

Cowen Initiates Coverage of NeoGenomics at Outperform

The investment bank said it expects the launch of NeoGenomics' minimal residual disease test will accelerate growth.

Exagen Prices $60.1M Public Offering of Stock

The company said it plans to use the proceeds to develop multiomics capabilities, including building out its clinical laboratory.

Roche to Acquire GenMark Diagnostics for $1.8B

Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.